Case series of patients treated with Transcranial Magnetic Stimulation (TMS) in the psychiatry department of the Ciudad Real General University Hospital during the period 2024-2025
D. E. Gerardino Salomon, C. Rodriguez-GomezIntroduction
This abstract presents a comprehensive overview of a case series examining the clinical application and outcomes of Transcranial Magnetic Stimulation (TMS) as a therapeutic intervention for patients with treatment-resistant depression (TRD), obsessive-compulsive disorder (OCD), and eating desorders (ED). The study, conducted at the Psychiatry Department of the Ciudad Real University General Hospital from 2024 to 2025.
Objectives
The primary objective of this case series was to evaluate the clinical application and outcomes of TMS in a cohort of patients with TRD, OCD, and ED who had not responded to traditional pharmacological treatments.
Methods
The methodology involved a retrospective analysis of patient data from individuals who underwent TMS treatment during the specified period. A total of 44 patients were included in the series, with a gender distribution showing a higher proportion of females. The age range of the patients was from 26 to 66 years, with the highest concentration of cases in the 40-50 age bracket. Protocols for depression, OCD and ED were distinctly applied, with specific parameters for frequency, pulses per train, number of trains, and inter-train intervals tailored to each condition, highlighting the personalized nature of the treatment. Patient outcomes were assessed through a validated questionary administered upon completion of the sessions. The results were categorized into three groups: remission, partial improvement, and no improvement.
Results
The findings were promising, with a significant proportion of patients achieving full remission. Specifically, 58.2% of the patients experienced remission, 31.6% showed partial improvement, and only 10.2% reported no improvement. These results are particularly notable given that the cohort consisted of patients who had not responded to previous pharmacological interventions, underscoring TMS’s potential as a powerful alternative or adjunct therapy. The data on the average number of sessions per outcome category revealed a trend toward better results with a higher number of sessions, with high improvement correlating with a higher average session count compared to partial or no improvement. This suggests a dose-response relationship.
Conclusions
Furthermore, the study confirmed that TMS is a well-tolerated technique with few side effects, reinforcing its status as a safe and non-invasive treatment modality. The consistency of these findings with those of previous, larger-scale international studies demonstrates the reproducibility and generalizability of TMS’s therapeutic benefits. However, as a case series, the study is limited by its small sample size. This limitation prevents rigorous statistical analysis and the drawing of definitive conclusions.
Disclosure of Interest
None Declared